ArticleCancers2026
Intraoperative Flow Cytometry for the Differentiation of Glioblastomas from Metastatic Brain Tumours: A Preliminary Prospective Study.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) and metastatic brain tumours are the two malignant intracranial lesions most frequently encountered in adult neurosurgical practice, and their intraoperative separation may be difficult when imaging is atypical, when no extracranial primary tumour is known, or when frozen-section examination is deferred or inconclusive. Intraoperative flow cytometry (iFC) is an emerging adjunct that provides a rapid, quantitative assessment of tumour DNA content and cell cycle distribution, with a preliminary result available within approximately 5-6 min of tissue receipt.
aimThe aim was to determine, in a preliminary prospective cohort, whether iFC-derived DNA ploidy and cell cycle parameters differ between GBM and brain metastases, and to quantify their discriminatory performance.
methodsiFC was applied to 52 patients operated on for intracranial tumours, including 40 glioblastomas and 12 brain metastases. Tumour samples were analysed for DNA index, G0/G1-phase fraction, and Tumour Index (S + G2/M phases) using the "Ioannina-protocol". Groups were compared with the Mann-Whitney U test. Discrimination was assessed by receiver operating characteristic (ROC) analysis.
resultsMetastases showed a higher DNA index (median 1.05, interquartile range [IQR] 1.00-1.32 versus 1.00, IQR 1.00-1.00;
conclusionsIn this small, single-centre preliminary study of 40 glioblastomas and only 12 metastases, iFC detected reproducible differences in DNA ploidy and cell cycle distribution at the group level. Overall discrimination was moderate, so that these parameters cannot at present support an individual-patient intraoperative diagnosis. DNA-based iFC should be regarded as a potential complement to standard intraoperative neuropathological assessment, and requires validation in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.